# Versatile halogenation via a C<sub>NHC</sub><sup>^</sup>C<sub>sp3</sub> palladacycle intermediate

Qiaoqiao Teng,\* Ziwei Liu, Haobin Song, Jiayu Liu, Yaru Zhao, Weihua Jiang, Han Vinh Huynh\* and Qi Meng\*

Jiangsu Key Laboratory of Advanced Catalytic Materials and Technology, School of Petrochemical Engineering, Changzhou University, Changzhou, 213164, China.

E-mail: tqq@cczu.edu.cn; mengqi@cczu.edu.cn

Department of Chemistry, National University of Singapore, 117543 Singapore, Republic of Singapore.

Email: chmhhv@nus.edu.sg

### **Table of Contents**

| Electron  | donating     | abilities | of    | the   | monodentate | and   | C <sub>NHC</sub> ^C <sub>sp3</sub> | bidentate |
|-----------|--------------|-----------|-------|-------|-------------|-------|------------------------------------|-----------|
| ligands   |              |           |       | ••••• |             | ••••• |                                    | S2        |
| Experime  | ntal section |           | ••••• | ••••• |             |       |                                    | S5        |
| NMR Spe   | ectra        |           |       |       |             |       |                                    | S16       |
| X-ray Dif | fraction Stu | idies     |       |       |             |       |                                    | S35       |

Electron donating abilities of the monodentate and CNHC<sup>A</sup>C<sub>*sp*3</sub> bidentate ligands. The <sup>i</sup>Pr<sub>2</sub>-bimy <sup>13</sup>C<sub>carbene</sub> resonances of complexes **3a-d** and **6** (HEP values) are in the range of 178.1–179.2 ppm (Table S1), which are at lower field compared to those of IMes (177.2 ppm) and IPr (177.5 ppm) suggesting stronger donating powers of the dialkyl substituted imidazolin-2-ylidenes.<sup>1</sup> A closer look at the HEP values shows that they increase in the order of **3a** < **6** < **3d** < **3b** < **3c** in line with an increasing electron donating power of the respective ligands. This difference clearly originates from the increasing positive inductive effects (+*I*) of the N<sub>3</sub> substituents in these ligands, which is -(CH<sub>2</sub>)<sub>2</sub>CN (**3a**) < -(CH<sub>2</sub>)<sub>2</sub>CH<sub>2</sub>BrCN (**6**) < -(CH<sub>2</sub>)<sub>3</sub>CN (**3d**) < -(CH<sub>2</sub>)<sub>2</sub>COOMe (**3b**) < -(CH<sub>2</sub>)<sub>2</sub>COPh (**3c**). The additional methylene group in **3d** makes the N<sub>3</sub> substituent and thus the whole carbene ligand more electron donating. The Br substitution, on the other hand, weakens the +*I* of the whole substituent in **6**.

| Ligand               | Complex    | n | R     | HEP/HEP2 <sup>a</sup> |
|----------------------|------------|---|-------|-----------------------|
| C <sub>NHC</sub>     | <b>3</b> a | 1 | CN    | 178.1                 |
|                      | <b>3</b> b | 1 | COOMe | $179.18^{b}$          |
|                      | 3c         | 1 | COPh  | $179.24^{b}$          |
|                      | <b>3</b> d | 2 | CN    | 178.5                 |
|                      | 6          | 2 | CN    | 178.2                 |
| Nimidazole           | 5          | - | -     | 161.8                 |
|                      | 10         | - | -     | 161.5                 |
| $C_{NHC}^{A}C_{sp3}$ | <b>4</b> a | 1 | CN    | 185.8                 |
|                      | <b>4b</b>  | 1 | COOMe | 189.4                 |
|                      | <b>4</b> c | 1 | COPh  | 187.8                 |
|                      | <b>4d</b>  | 2 | CN    | 188.4                 |

**Table S1** Summary of the  ${}^{i}Pr_{2}$ -bimy  ${}^{13}Ccarbene signals (HEP& HEP2)$  in complexes **3**-10.

<sup>*a*</sup>Measured in CDCl<sub>3</sub> and internally referenced to the solvent signal at 77.7 ppm. <sup>*b*</sup>The second decimal was kept for comparison of closer values. Detailed discussion on the standard deviations of HEP can be found in references 1.

The order of the -(CH<sub>2</sub>)<sub>2</sub>R groups in the monodentate NHC ligands is not easy to rationalize at first sight but is undoubtedly determined by the inductive effects of the R groups. By using substituted bicyclooctane carboxylic acids instead of substituted benzoic acids, Hansch and Leo could successfully deconvolute the  $\sigma$  Hammett values into their inductive components.<sup>2</sup> Both the  $\sigma_m$  and  $\sigma_p$  values of the present R groups rank in the order -CN (0.56, 0.66) > -CO<sub>2</sub>Me (0.37, 0.45) > -COPh (0.34, 0.43), suggesting greater *-I* effects of the -CN followed by the -CO<sub>2</sub>Me and the -COPh substituents. This order is reflected in the HEP values of the monodentate NHC ligands, which only differ in these remote substituents six bonds away from the reporter atom.

The HEP value for **5** was found at a much higher field at 161.8 ppm due to the significantly weaker electron donating ability of N donors in general. For comparison, we have also prepared the non-brominated analogue  $[PdBr_2(^{i}Pr_2-bimy)(Bn-Imi)]$  (**10**) bearing a simple *N*-benzylimidazole. The HEP of the latter is at higher field of 161.5 ppm, suggesting a net electron donating nature of the Br substituent on the imidazole ring due to the dominance of the +*M* effect.



Figure S1. Optimized structure of 4c at the B3LYP/def2-TZVP level.

The HEP2 order within the chelate complexes **4a-b** shows a slightly different trend with  $-(CH_2)_2CN$  (**4a**, L1) <  $-(CH_2)_2COPh$  (**4c**, L3) <  $-(CH_2)_3CN$  (**4d**, L4) < -(CH<sub>2</sub>)<sub>2</sub>COOMe (**4b**, L2) (Figure 2 and Table S1). Surprisingly, the least inductively withdrawing -COPh group leads to a somewhat smaller HEP2 value. This is probably due to the shielding effect exerted by the phenyl group near the reporter carbon atom, which induces a shift to the higher field. Regrettably, single crystals of **4c** were not obtained but geometry optimization using DFT calculation confirmed the spatial arrangement (Figure S1).<sup>3</sup> Such an anisotropy effect has been observed for arylated expanded-ring NHCs and represents a limitation of the HEP method.<sup>4</sup>

#### **Experimental Section**.

**General Considerations.** Unless otherwise noted, all operations were performed without taking precautions to exclude air and moisture, and all solvents and chemicals were used as received. <sup>1</sup>H and <sup>13</sup>C{<sup>1</sup>H} NMR spectra were recorded at 298 K on a Bruker ACF 300 spectrometer or AMX 500 spectrophotometer, and the chemical shifts ( $\delta$ ) were internally referenced to the residual solvent signals relative to tetramethylsilane. ESI mass spectra were measured using a Finnigan MAT LCQ spectrometer. Elemental analyses were performed on an ElementarVario Micro Cube elemental analyzer. 3-(1*H*-imidazol-1-yl) propanentrile <sup>5</sup>, methyl 3-(1*H*-imidazol-1-yl) propanoate, 3-(1*H*-imidazol-1-yl)-1-phenylpropan-1-one were prepared following literature procedures. <sup>6</sup> DFT calculation was performed using Gaussian 09<sup>7</sup> with B3LYP/def2-TZVP. The ground state was validated by the absence of imaginary frequencies.

**General procedure for the preparation of salt precursors.** For **1a–1c**, monosubstituted imidazole (1.00 mmol) and benzyl bromide (5.00 mmol) were dissolved in toluene (5 mL) in a sealed tube and stirred at 90 °C overnight. The resulting suspension was separated and the residue washed with toluene, diethyl ether or DCM before drying under vacuum to afford the products. Salt **1d** was prepared in analogous way from 1benzylimidazole (475 mg, 3.00 mmol) and 4-bromobutyronitrile (327 µL, 3.30 mmol).



1a, white sticky solid (232 mg, 0.85 mmol, 85%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD):  $\delta$  9.83 (s, <sup>1</sup>H, NCHN), 7.83 (d, 1H, <sup>3</sup>*J* = 2 Hz, Imi-H), 7.30–7.34 (m, 6H, Ar-H & Imi-H), 5.40 (s, 2H, NCH<sub>2</sub>Ph), 4.66–4.71 (m, 2H, NCH<sub>2</sub>), 3.17–3.22 (m, 2H, NCCH<sub>2</sub>); <sup>13</sup>C{<sup>1</sup>H} NMR (75 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD):  $\delta$  137.3 (NCHN), 133.0, 130.2, 130.0, 129.3, 123.8, 122.8 (Ar-C), 117.3 (CN), 54.1, 45.9 (CH<sub>2</sub>), 20.4 (CCN). Anal. Calcd. for C<sub>13</sub>H<sub>14</sub>BrN<sub>3</sub>: C 53.44, H 4.83, N 14.38; found: C 53.67,

H 4.82, N 14.02. MS-EI (m/z):  $[M - Br]^+$  calcd for C<sub>13</sub>H<sub>14</sub>N<sub>3</sub> 212, found 212.



after multiple tests). MS-EI (m/z):  $[M - Br]^+$  calcd for C<sub>14</sub>H<sub>17</sub>BrN<sub>2</sub>O<sub>2</sub> 245, found 245.



1c, white solid (286 mg, 0.77 mmol, 77%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  10.42 (s, 1H, NCHN), 7.94 (d, <sup>3</sup>*J* = 3 Hz, 2H, Ar-H), 7.68 (s, 1H, Imi-H), 7.51–7.55 (m, 1H, Ar-H), 7.33–7.49 (m, 7H, Ar-H), 7.19 (s, 1H, Imi-H), 5.46 (s, 2H, NCH<sub>2</sub>), 4.76 (d,  ${}^{3}J = 6$  Hz, 2H, NCH<sub>2</sub>), 3.84 (d,  ${}^{3}J = 6$  Hz, 2H, CH<sub>2</sub>);  ${}^{13}C{}^{1}H{}$  NMR (75 MHz, CDCl<sub>3</sub>): *δ* 197.6 (CO), 137.9 (NCHN), 136.1, 134.6, 133.4, 130.1, 130.1, 129.4, 129.4, 128.9, 124.5, 121.8 (Ar-C), 54.1, 45.4, 39.9 (CH<sub>2</sub>). Anal. Calcd. for C<sub>19</sub>H<sub>19</sub>BrN<sub>2</sub>O: C 61.47, H 5.16, N 7.55; found: C 61.58, H 5.43,

N 7.76. MS-EI (m/z):  $[M - Br]^+$  calcd for C<sub>19</sub>H<sub>19</sub>N<sub>2</sub>O 291, found 291.



General procedure for the preparation of hetero-bis(carbene) complexes. Salt precursor 1 (294 mg, 1.00 mmol), dimeric complex 2 (470 mg, 0.50 mmol) and Ag<sub>2</sub>O (139 mg, 0.59 mmol) were suspended in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) and stirred overnight. The resulting suspension for 1a and 1d were directly filtered and dried to give 3a and 3d, respectively, while those for 3b and 3c need further purification by column chromatography. SiO<sub>2</sub>: PE/EA/DCM V/V/V 2/1/1 (3b), 8/1/1 (3c). All are yellow solids.



**3a**, 616 mg, 0.93 mmol, 93%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  7.52–7.59 (m, 4H, Ar-H), 7.33–7.45 (m, 3H, Ar-H), 7.19–7.22 (m, 2H, Ar-H), 7.02 (d, <sup>3</sup>*J* = 2 Hz, 1H, Imi-H), 6.77 (d, <sup>3</sup>*J* = 2 Hz, 1H, Imi-H), 6.13 (m, <sup>3</sup>*J* = 7 Hz, 1H, NCH), 5.99 (m, <sup>3</sup>*J* = 7 Hz, 1H, NCH), 5.76 (s, 2H, NCH<sub>2</sub>), 4.88 (t, <sup>3</sup>*J* = 7 Hz, 2H, NCH<sub>2</sub>), 3.40 (t, <sup>3</sup>*J* = 7 Hz, 2H, NCCH<sub>2</sub>), 1.84 (d, <sup>3</sup>*J* = 7 Hz, 6H, CH<sub>3</sub>), 1.68 (d, <sup>3</sup>*J* = 7 Hz, 6H, CH<sub>3</sub>); <sup>13</sup>C{<sup>1</sup>H}

NMR (75 MHz, CDCl<sub>3</sub>): δ178.1 (C<sub>carbene-benz</sub>), 172.9 (C<sub>carbene-imi</sub>), 136.2, 134.21, 134.17, 129.6, 129.3, 129.1, 122.8, 122.2, 121.1 (Ar-C, two are coincident), 117.9 (CN), 113.32, 113.27 (Ar-C), 55.4, 54.8, 54.5, 47.4, 21.7, 21.6, 20.4 (CH, CH<sub>2</sub> and CH<sub>3</sub>). Anal. Calcd. for C<sub>26</sub>H<sub>31</sub>Br<sub>2</sub>N<sub>5</sub>Pd: C 45.94, H 4.60, N 10.30; found: C 45.78, H 4.83, N 10.06. MS-EI (*m/z*): [M – Br]<sup>+</sup> calcd for C<sub>26</sub>H<sub>31</sub>BrN<sub>5</sub>Pd 598, found 598.

**3b**, 519 mg, 0.73 mmol, 73%. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  7.51–7.57 (m, 4H, Ar-H), 7.33–7.42 (m, 3H, Ar-H), 7.16–7.21 (m, 2H, Ar-H), 7.00 (d, <sup>3</sup>*J* = 2 Hz, 1H, Imi-H), 6.70 (d, <sup>3</sup>*J* = 2 Hz, 1H, Imi-H), 6.22 (m, <sup>3</sup>*J* = 7 Hz, 1H, NCH), 5.99 (m, <sup>3</sup>*J* = 7 Hz, 1H, NCH), 5.75 (s, 2H, NCH<sub>2</sub>), 4.86 (t, <sup>3</sup>*J* = 7 Hz, 1H, NCH<sub>2</sub>), 3.75 (s, 3H, OCH<sub>3</sub>), 3.31 (t, <sup>3</sup>*J* = 7 Hz, 2H, COCH<sub>2</sub>), 1.81 (d, <sup>3</sup>*J* = 7 Hz, 6H, CH<sub>3</sub>), 1.68 (d, <sup>3</sup>*J* = 7 Hz, 6H, CH<sub>3</sub>); <sup>13</sup>C {<sup>1</sup>H} NMR (125 MHz, CDCl<sub>3</sub>):  $\delta$  179.2 (C<sub>carbene-benz</sub>), 172.4 (CO), 171.6 (C<sub>carbene-imi</sub>), 136.7, 134.3, 134.2, 129.5, 129.3, 128.9, 122.9, 122.6, 121.3, 113.2 (Ar-C, three are coincident), 55.3, 54.6, 54.4, 52.7, 47.1, 36.2, 21.7, 21.6 (CH, CH<sub>2</sub> and CH<sub>3</sub>). Anal. Calcd. for C<sub>27</sub>H<sub>34</sub>Br<sub>2</sub>N<sub>4</sub>O<sub>2</sub>Pd: C 45.49, H 4.81, N 7.86; found: C 45.78, H 4.83, N 7.75. MS-EI (*m*/*z*): [M – Br]<sup>+</sup> calcd for C<sub>27</sub>H<sub>34</sub>BrN<sub>4</sub>O<sub>2</sub>Pd 631, found 631.



**3c**, 577 mg, 0.76 mmol, 76%. Single crystals were obtained by slow evaporation of a concentrated solution in THF and hexane. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  8.06 (d, <sup>3</sup>*J* = 7 Hz 2H, Ar-H), 7.35–7.53 (m, 10H, Ar-H), 7.16–7.19 (m, 2H, Ar-H), 7.04 (br-s, 1H, Imi-H), 6.68 (br-s, 1H, Imi-H), 6.17 (m, <sup>3</sup>*J* = 7 Hz, 1H, NCH), 6.01 (m, <sup>3</sup>*J* = 7 Hz, 1H, NCH), 5.75 (s, 2H, NCH<sub>2</sub>), 5.01 (t, <sup>3</sup>*J* = 7 Hz, 2H, NCH<sub>2</sub>),

4.01 (t,  ${}^{3}J = 7$  Hz, 2H, CH<sub>2</sub>CO), 1.70 (d,  ${}^{3}J = 7$  Hz, 12H, CH<sub>3</sub>);  ${}^{13}C\{{}^{1}H\}$  NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  198.6 (C=O), 179.2 (C<sub>carbene-benz</sub>), 171.2 (C<sub>carbene-imi</sub>), 137.1, 136.6, 134.2, 129.5, 129.4, 129.3, 128.9, 128.8, 123.3, 122.6, 121.0, 113.2 (Ar-C, two are coincident), 55.2, 54.5, 54.4, 46.5, 40.9, 21.6, 21.5 (CH, CH<sub>2</sub> and CH<sub>3</sub>). Anal. Calcd. for : C<sub>32</sub>H<sub>36</sub>Br<sub>2</sub>N<sub>4</sub>OPd: C 50.65, H 4.78, N 7.38; found: C 50.78, H 4.99, N 7.36. MS-EI (*m/z*): [M – Br]<sup>+</sup> calcd for C<sub>32</sub>H<sub>36</sub>Br<sub>2</sub>N<sub>4</sub>OPd 677, found 677.



**3d**, 652 mg, 0.94 mmol, 94%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  7.50–7.58 (m, 4H, Ar-H), 7.35–7.43 (m, 3H, Ar-H), 7.17–7.20 (m, 2H, Ar-H), 6.94 (d, <sup>3</sup>*J* = 2 Hz, 1H, Imi-H), 6.78 (d, <sup>3</sup>*J* = 2 Hz, 1H, Imi-H), 6.11 (m, <sup>3</sup>*J* = 7 Hz, 1H, NCH), 6.03 (m, <sup>3</sup>*J* = 7 Hz, 1H, NCH), 5.81 (s, 2H, NCH<sub>2</sub>), 4.67 (t, <sup>3</sup>*J* = 7 Hz, 1H, NCH<sub>2</sub>), 2.52–2.65 (m, 4H, NCCH<sub>2</sub> & CH<sub>2</sub>), 1.81 (d, <sup>3</sup>*J* = 7 Hz, 6H, CH<sub>3</sub>), 1.63 (d, <sup>3</sup>*J* = 7 Hz, 6H, CH<sub>3</sub>);

<sup>13</sup>C{<sup>1</sup>H} NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  178.5 (C<sub>carbene-benz</sub>), 171.8 (C<sub>carbene-imi</sub>), 136.5, 134.1, 134.2, 129.6, 129.0, 128.9, 122.7, 122.5, 122.0 (Ar-C, two are coincident), 119.5 (CN), 113.3, 113.2 (Ar-C), 55.3, 54.6, 54.4, 49.8, 27.1, 21.66, 21.45, 15.3 (CH, CH<sub>2</sub> and CH<sub>3</sub>). Anal. Calcd. for C<sub>27</sub>H<sub>33</sub>Br<sub>2</sub>N<sub>5</sub>Pd: C 46.74, H 4.79, N 10.09; found: C 46.87, H 4.98, N 10.45. MS-EI (*m/z*): [M – Br]<sup>+</sup> calcd for C<sub>27</sub>H<sub>33</sub>BrN<sub>5</sub>Pd 612, found 612.



Complex **3a** (85 mg, 0.12 mmol) was dissolved in CH<sub>3</sub>CN (5 mL) and THF (5 mL) before NaOH (8 mg, 0.20 mmol) was added. The suspension was stirred overnight, and the solvent was removed by vacuum distillation before DCM (10 mL) was added, which was filtered, dried and washed

with Et<sub>2</sub>O (3 × 5 mL) to afford **4a** as an off-white solid (65 mg, 0.11 mmol, 98%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  7.61–7.64 (m, 1H, Ar-H), 7.56–7.58 (m, 1H, Ar-H), 7.45–7.47 (m, 2H, Ar-H), 7.30–7.40 (m, 3H, Ar-H), 7.20–7.23 (m, 2H, Ar-H), 6.99 (d, <sup>3</sup>*J* = 2 Hz, 1H, Imi-H), 6.72 (d, <sup>3</sup>*J* = 2 Hz, 1H, Imi-H), 5.85–6.08 (m, 4H, NCH & NCH<sub>2</sub>), 4.08–4.20 (m, 2H, NCH<sub>2</sub>), 2.95–2.99 (m, 1H, CH), 1.87 (d, <sup>3</sup>*J* = 7 Hz, 3H, CH<sub>3</sub>), 1.74–1.79 (m, 9H, CH<sub>3</sub>); <sup>13</sup>C{<sup>1</sup>H} NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$ 185.8 (C<sub>carbene-benz</sub>), 175.9 (C<sub>carbene-ini</sub>), 137.6, 134.7, 134.1, 129.4, 129.3, 128.6, 127.2, 122.7, 122.6, 121.9 (Ar-C), 118.4 (CN), 113.7, 113.2 (Ar-C), 54.9, 54.8, 54.6, 54.5, 22.4, 22.1, 21.8, 21.6 (CH, CH<sub>2</sub> and CH<sub>3</sub>), 8.0 (Pd-C). Anal. Calcd. for C<sub>26</sub>H<sub>30</sub>BrN<sub>5</sub>Pd: C 52.14, H 5.05, N 11.69; found: C 52.46, H 4.97, N 11.58. MS-EI (*m*/*z*): [M – Br]<sup>+</sup> calcd for C<sub>26</sub>H<sub>30</sub>BrN<sub>5</sub>Pd 518, found 518.



Complex **3b** (42 mg, 0.06 mmol) and NaOH (8 mg, 0.20 mmol) were suspended in CH<sub>3</sub>CN (5 mL) and stirred for 4 h. The resulting suspension was filtered, concentrated and subjected to flash chromatography (SiO<sub>2</sub>: PE/EA/DCM V/V/V 8/1/1 to MeOH/DCM V/V 1/30) to give complex **4b** 

as an off-white solid (13 mg, 0.02 mmol, 34%). Single crystals were obtained by slow evaporation of a concentrated solution in THF and hexane. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  7.57–7.60 (m, 2H, Ar-H), 7.43–7.46 (m, 2H, Ar-H), 7.29–7.37 (m, 3H, Ar-H), 7.16–7.21 (m, 2H, Ar-H), 6.99 (d, <sup>3</sup>*J* = 2 Hz, 1H, Imi-H), 6.69 (d, <sup>3</sup>*J* = 2 Hz, 1H, Imi-H), 6.12 (m, <sup>3</sup>*J* = 7 Hz, 1H, NCH), 5.93 (br-s, 2H, NCH<sub>2</sub>), 5.80 (m, <sup>3</sup>*J* = 7 Hz, 1H, NCH), 4.41 (dd, <sup>3</sup>*J* = 7 Hz, <sup>2</sup>*J* = 12 Hz, 1H, NCHH), 4.00 (dd, <sup>3</sup>*J* = 7 Hz, <sup>2</sup>*J* = 12 Hz, 1H, NCH), NCH*H*), 3.53 (t, <sup>3</sup>*J* = 7 Hz, 1H, COCH), 2.96 (s, 3H, OCH<sub>3</sub>), 1.75–1.82 (m, 9H, CH<sub>3</sub>),

1.71 (d,  ${}^{3}J = 7$  Hz, 3H, CH<sub>3</sub>);  ${}^{13}C\{{}^{1}H\}$  NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  189.4 (C<sub>carbene-benz</sub>), 180.3 (C=O), 175.7 (C<sub>carbene-imi</sub>), 138.2, 134.3, 134.0, 129.2, 128.4, 122.4, 122.3, 121.4, 118.3, 113.4, 113.1 (Ar-C, two are coincident), 54.8, 54.6, 54.3, 54.2, 50.7 (CH and CH<sub>2</sub>), 31.9 (Pd-C), 22.0, 21.7, 21.3, 21.1 (CH<sub>2</sub> and CH<sub>3</sub>). Anal. Calcd. for C<sub>27</sub>H<sub>33</sub>BrN<sub>4</sub>O<sub>2</sub>Pd: C 51.32; H 5.26; N 8.87; found: C 51.48, H 5.62, N 8.53. MS-EI (*m/z*): [M – Br]<sup>+</sup> calcd for C<sub>27</sub>H<sub>334</sub>O<sub>2</sub>Pd 551, found 551.



4c was prepared in analogy to 4a from 3c (60 mg, 0.08 mmol), NaOH (6 mg, 0.14 mmol) as a yellow solid (53 mg, 0.08 mmol, 98%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 7.57 (d, <sup>3</sup>J = 8 Hz, 1H, Ar-H), 7.41–7.45 (m, 4H, Ar-H), 7.30–7.37 (m, 4H, Ar-H), 7.14–7.19 (m, 3H, Ar-H), 7.06 (d, <sup>3</sup>J = 2 Hz,

1H, Imi-H), 6.87 (t,  ${}^{3}J = 8$  Hz, 2H, Ar-H), 6.71 (d,  ${}^{3}J = 2$  Hz, 1H, Imi-H), 6.19 (m,  ${}^{3}J = 7$  Hz, 1H, NCH), 5.93 (d,  ${}^{3}J = 15$  Hz, 1H, NCH), 5.86 (d,  ${}^{3}J = 15$  Hz, 1H, NCH*H*), 5.35 (m,  ${}^{3}J = 7$  Hz, 1H, NCH), 4.70–4.73 (m, 1H, CHCO), 4.30–4.35 (m, 2H, NCH<sub>2</sub>), 1.82 (d,  ${}^{3}J = 7$  Hz, 3H, CH<sub>3</sub>), 1.75 (d,  ${}^{3}J = 7$  Hz, 3H, CH<sub>3</sub>), 1.53 (d,  ${}^{3}J = 7$  Hz, 3H, CH<sub>3</sub>), 1.75 (d,  ${}^{3}J = 7$  Hz, 3H, CH<sub>3</sub>), 1.53 (d,  ${}^{3}J = 7$  Hz, 3H, CH<sub>3</sub>), 0.78 (d,  ${}^{3}J = 7$  Hz, 3H, CH<sub>3</sub>);  ${}^{13}C{}^{1}H$  NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  201.9 (C=O), 187.8 (C<sub>carbene-benz</sub>), 175.2 (C<sub>carbene-imi</sub>), 138.8, 138.1, 134.8, 134.0, 131.7, 129.2, 129.1, 128.5, 128.2, 128.0, 122.4, 122.3, 121.3, 118.3, 113.3, 113.0 (Ar-C), 54.5, 54.4, 54.3, 54.2, 22.1, 21.9, 21.7 (CH, CH<sub>2</sub> and CH<sub>3</sub>), 21.2 (Pd-C), 20.4 (CH<sub>3</sub>). Anal. Calcd. for : C<sub>32</sub>H<sub>35</sub>BrN<sub>4</sub>OPd: C 56.69, H 5.20, N 8.26; found: C 56.89, H 5.48, N 8.46. MS-EI (*m/z*): [M – Br]<sup>+</sup> calcd for C<sub>32</sub>H<sub>35</sub>N<sub>4</sub>OPd 597, found 597.



Under nitrogen atmosphere, complex **3d** (310 mg, 0.45 mmol) was dissolved in THF (15 mL) before t-BuOK (76 mg, 0.67 mmol) was added and reacted at 60°C for 12 h. The solvent was removed by vacuum distillation to give a crude product before DCM (10 mL) was added. The

suspension was filtered, and the filtrate was dried and washed with Et<sub>2</sub>O (10 mL  $\times$  3)

to afford **4d** as a yellow solid (261mg, 0.43 mmol, 96%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  7.54–7.60 (m, 2H, Ar-H), 7.47–7.49 (m, 2H, Ar-H), 7.32–7.42 (m, 3H, Ar-H), 7.18–7.22 (m, 2H, Ar-H), 6.88 (d, <sup>3</sup>*J* = 2 Hz, 1H, Imi-H), 6.74 (d, <sup>3</sup>*J* = 2 Hz, 1H, Imi-H), 6.17 (d, <sup>2</sup>*J* = 15 Hz, 1H, C*H*H), 5.85–5.96 (m, <sup>3</sup>*J* = 7 Hz, 2H, NCH), 5.59 (d, <sup>2</sup>*J* = 15 Hz, 1H, CH*H*), 4.08–4.15 (m, 2H, NCH<sub>2</sub>), 2.66 (t, <sup>3</sup>*J* = 7 Hz 1H, CH), 2.09–2.20 (m, 1H, CH<sub>2</sub>), 1.66–1.79 (m, 13H, CH<sub>2</sub> & CH<sub>3</sub>); <sup>13</sup>C{<sup>1</sup>H} NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  188.4 (C<sub>carbene-benz</sub>), 175.9 (C<sub>carbene-imi</sub>), 137.8, 134.4, 134.0, 129.4, 129.1, 128.8, 128.4, 122.7, 122.6, 121.5 (Ar-C), 120.9 (CN), 113.5, 113.2 (Ar-C), 55.2, 54.6, 54.5, 52.5, 30.6, 22.3, 22.0, 21.7, 21.5 (CH, CH<sub>2</sub> and CH<sub>3</sub>), -2.3 (Pd-C). Anal. Calcd. for C<sub>27</sub>H<sub>32</sub>BrN<sub>5</sub>Pd: C 52.91, H 5.26, N 11.43, found: C 52.79, H 5.60, N 11.67. MS-EI (*m*/*z*): [M – Br]<sup>+</sup> calcd for C<sub>27</sub>H<sub>32</sub>BrN<sub>5</sub>Pd 532, found 532.



Complex 4a (60 mg, 0.10 mmol) was dissolved in DCM (5 mL) before bromine (6  $\mu$ L, 0.12 mmol) in CHCl<sub>3</sub> (5 mL) were added dropwise. The mixture was stirred for 2 h, concentrated and subjected to

column chromatography (SiO<sub>2</sub>: PE/EA/DCM V/V/V 8/1/1 to 4/1/1) to give complex **5** as a yellow solid (54 mg, 0.08 mmol, 76%). Single crystals were obtained by slow evaporation of a concentrated solution in CHCl<sub>3</sub> and hexane. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  7.56–7.79 (m, 2H, Ar-H), 7.36–7.38 (m, 3H, Ar-H), 7.30 (d, <sup>3</sup>*J* = 2 Hz, 1H, Imi-H), 7.17–7.22 (m, 4H, Ar-H), 6.90 (d, <sup>3</sup>*J* = 2 Hz, 1H, Imi-H), 6.45 (m, <sup>3</sup>*J* = 7 Hz, 2H, NCH), 5.13 (s, 2 H, NCH<sub>2</sub>), 1.81 (d, <sup>3</sup>*J* = 7 Hz, 12H, CH<sub>3</sub>); <sup>13</sup>C {<sup>1</sup>H} NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  161.8 (C<sub>carbene</sub>), 134.5, 134.2, 131.7, 129.9, 129.5, 128.4, 122.9, 122.8, 113.3 (Ar-C), 55.1, 53.0, 21.4 (CH, CH<sub>2</sub> and CH<sub>3</sub>). Anal. Calcd. for C<sub>23</sub>H<sub>27</sub>Br<sub>3</sub>N<sub>4</sub>Pd: C 39.15, H 3.86, N 7.94; found: C 39.53, H 3.98, N 7.87. MS-EI (*m*/*z*): [M –L– Br]<sup>+</sup> calcd for C<sub>13</sub>H<sub>18</sub>BrN<sub>2</sub>Pd 387, found 387.



Complex **4d** (91 mg, 0.15 mmol) was dissolved in DCM (5 mL) before bromine (6  $\mu$ L, 0.12 mmol) in CHCl<sub>3</sub> (5 mL) were added dropwise. The mixture was stirred for 2 h, concentrated and subjected to column chromatography (SiO<sub>2</sub>: PE/EA/DCM V/V/V 8/1/1) to give complex **6** as a yellow solid (58 mg, 0.08 mmol, 50%). <sup>1</sup>H NMR (300 MHz,

CDCl<sub>3</sub>):  $\delta$  7.51–7.60 (m, 4H, Ar-H), 7.36–7.45 (m, 3H, Ar-H), 7.18–7.20 (m, 2H, Ar-H), 6.93 (d,  ${}^{3}J = 2$  Hz, 1H, Imi-H), 6.78 (d,  ${}^{3}J = 2$  Hz, 1H, Imi-H), 5.99–6.16 (m,  ${}^{3}J = 7$  Hz 2H, NCH), 5.87 (d,  ${}^{2}J = 15$  Hz, 1H, NCHH), 5.79 (d,  ${}^{2}J = 15$  Hz, 1H, NCHH), 4.69–4.76 (m, 2H, NCH<sub>2</sub>), 3.27–3.38 (m, 1H, CHH), 3.06–3.18 (m, 1H, CHH), 1.78–1.81 (m, 6H, CH<sub>3</sub>), 1.79 (d,  ${}^{3}J = 7$  Hz, 6H, CH<sub>3</sub>);  ${}^{13}C{}^{1}H{}$  NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$ 178.2 (C<sub>carbene-benz</sub>), 172.0 (C<sub>carbene-imi</sub>), 136.4, 134.2, 134.0, 129.6, 129.0, 128.9, 122.8, 122.7, 122.1 (Ar-C, two are coincident), 117.5 (CN), 113.4, 113.3 (Ar-C), 55.4, 54.7, 54.5, 48.5, 37.7, 25.1, 21.6, 21.5, 21.4 (CH, CH<sub>2</sub> and CH<sub>3</sub>, two are coincident). Anal. Calcd. for C<sub>27</sub>H<sub>32</sub>Br<sub>3</sub>N<sub>5</sub>Pd: C 41.97, H 4.17, N 9.06; found: C 41.87, H 4.52, N 8.98. MS-EI (*m*/*z*): [M – Br]<sup>+</sup> calcd for C<sub>27</sub>H<sub>32</sub>Br<sub>3</sub>N<sub>5</sub>Pd 692, found 692.



Complex 4a (120 mg, 0.20 mmol) and KI (100 mg, 0.20 mmol) were suspended in  $CH_3CN$  (10 mL). The suspension was stirred overnight, and the solvent was removed by vacuum evaporation before DCM (10 mL) was added, which was filtered afford 7a as a yellow solid (127 mg, 0.20

mmol 98%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$ 7.55–7.63 (m, 3H, Ar-H), 7.42–7.45 (m, 2H, Ar-H), 7.37–7.39 (m, 2H, Ar-H), 7.31–7.34 (m, 2H, Ar-H), 7.19–7.23 (m, 2H, Ar-H), 7.02 (d, <sup>3</sup>*J* = 2 Hz, 1H, Imi-H), 6.73 (d, <sup>3</sup>*J* = 2 Hz, 1H, Imi-H), 5.89–5.97 (m, 4H, NCH & NCH<sub>2</sub>), 4.18–4.21 (m, 2H, NCH<sub>2</sub>), 2.98–3.02 (m, 1H, CH), 1.84 (d, <sup>3</sup>*J* = 7 Hz, 3H, CH<sub>3</sub>), 1.71–1.76 (m, <sup>3</sup>*J* = 7 Hz, 9H, CH<sub>3</sub>); <sup>13</sup>C{<sup>1</sup>H} NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  184.5 (C<sub>carbene-benz</sub>), 176.4 (C<sub>carbene-imi</sub>), 137.4, 134.8, 134.2, 129.2, 129.1, 128.6, 127.1, 122.6, 122.6, 121.8 (Ar-C), 118.5 (CN), 113.6, 113.1 (Ar-C), 56.5, 54.8, 54.7, 54.3,

22.5, 22.0, 21.3, 21.04 (CH, CH<sub>2</sub> and CH<sub>3</sub>), 11.8 (Pd-C). Anal. Calcd. for C<sub>26</sub>H<sub>30</sub>IN<sub>5</sub>Pd: C 48.35, H 4.68, N 10.84; found: C 48.13, H 4.92, N 10.98. MS-EI (*m/z*): [M − I]<sup>+</sup> calcd for C<sub>26</sub>H<sub>30</sub>N<sub>5</sub>Pd 518, found 518.



Complex **7d** was prepared in analogy to **7a** from **4d** (61 mg, 0.10 mmol) and KI (83 mg, 0.50 mmol). Yield: 63 mg, 0.10 mmol, 95%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  7.53–7.58 (m, 2H, Ar-H), 7.45–7.47 (m, 2H, Ar-H), 7.38–7.42 (m, 3H, Ar-H), 7.18–7.22 (m, 2H, Ar-H), 6.90 (d, <sup>3</sup>*J* = 2 Hz, 1H, Imi-H),

6.76 (d,  ${}^{3}J = 2$  Hz, 1H, Imi-H), 6.07 (d,  ${}^{3}J = 15$  Hz, 1H, NCH*H*), 5.75–5.81 (m,  ${}^{3}J = 7$  Hz, 2H, NCH), 5.61 (d,  ${}^{3}J = 15$  Hz, 1H, NC*H*H), 4.13–4.14 (m, 2H, NCH<sub>2</sub>), 2.63 (t,  ${}^{3}J = 7$  Hz, 1H, CH), 2.12–2.13 (m, 1H, CH<sub>2</sub>), 1.67–1.76 (m, 13H, CH<sub>2</sub> & CH<sub>3</sub>);  ${}^{13}C{}^{1}H$ NMR (75 MHz,CDCl<sub>3</sub>):  $\delta$  187.9 (C<sub>carbene-benz</sub>), 177.1 (C<sub>carbene-imi</sub>), 137.5, 134.6, 134.2, 129.4, 129.3, 128.9, 128.5, 122.6, 122.5, 121.6 (Ar-C), 120.8 (CN), 113.5, 113.2 (Ar-C), 56.4, 54.5, 54.4, 52.9, 30.6, 22.3, 22.0, 21.7, 21.5 (CH, CH<sub>2</sub> and CH<sub>3</sub>), 0.56 (Pd-C). Anal. Calcd. for C<sub>27</sub>H<sub>32</sub>IN<sub>5</sub>Pd: C 49.14, H 4.89, 10.61, found: C 49.49, H 5.04, N 10.38. MS-EI (*m/z*): [M – I]<sup>+</sup> calcd for C<sub>27</sub>H<sub>32</sub>N<sub>5</sub>Pd 532, found 532.



Complex 7a (128 mg, 0.20 mmol) was dissolved in DCM (15 mL) before iodine (60 mg, 0.24 mmol) in CHCl<sub>3</sub>(10 mL) were added dropwise. The mixture was stirred for 2 h, concentrated and subjected to column

chromatography (SiO<sub>2</sub>: PE/EA V/V 10/1) to give complex **8** as a yellow solid (52 mg, 0.06 mmol, 31%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$ 7.55 (br-s, 2H, Ar-H), 7.31–7.37 (m, 4H, Ar-H), 7.17 (br-s, 4H, Ar-H & Imi-H), 6.98 (br-s, 1H, Imi-H), 6.26 (br-s, 2H, NCH), 5.14 (s, 2 H, NCH<sub>2</sub>), 1.78 (d, <sup>3</sup>*J* = 5 Hz, 12H, CH<sub>3</sub>); <sup>13</sup>C{<sup>1</sup>H} NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$ 159.4 (C<sub>carbene</sub>), 134.8, 134.7, 134.3, 129.9, 129.4, 128.2, 124.2, 122.6, 113.2 (Ar-C), 55.0, 21.4 (CH, CH<sub>2</sub> and CH<sub>3</sub>, two are coincident). Anal. Calcd. for C<sub>23</sub>H<sub>27</sub>I<sub>3</sub>N<sub>4</sub>Pd: C 32.63, H 3.21, N 6.62; found: C 32.53, H 3.08, N 6.44. MS-EI (*m/z*): [M – L+ I]<sup>-</sup> calcd

for C13H28I3N2Pd 689, found 689.



Complex **7d** (198 mg, 0.30 mmol) was dissolved in DCM (15 mL) before iodine (91 mg, 0.36 mmol) in CHCl<sub>3</sub> (5 mL) were added dropwise. The mixture was stirred for 2 h, concentrated and subjected to column chromatography (SiO<sub>2</sub>: PE/EA V/V 10/1) to give complex **9** as a yellow solid (88 mg, 0.10 mmol, 32%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  7.51–7.58 (m, 4H, Ar-H), 7.39–7.42 (m, 3H, Ar-H),

7.18–7.20 (m, 2H, Ar-H), 6.99 (d,  ${}^{3}J = 2$  Hz, 1H, Imi-H), 6.78 (d,  ${}^{3}J = 2$  Hz, 1H, Imi-H), 5.77–5.90 (m,  ${}^{3}J = 7$  Hz, 2H, NCH), 5.73 (d,  ${}^{2}J = 15$  Hz, 1H, NC*H*H), 5.66 (d,  ${}^{2}J = 15$  Hz, 2H, NCH*H*), 4.58 (t,  ${}^{2}J = 6$  Hz, 2H, CH<sub>2</sub>), 4.37 (t,  ${}^{2}J = 7$  Hz, 1H, NCCH), 3.12–3.20 (m, 1H, C*H*H), 2.95–3.02 (m, 1H, CH*H*), 1.77 (d,  ${}^{3}J = 7$  Hz, 6H, CH<sub>3</sub>), 1.63–1.66 (m, 6H, CH<sub>3</sub>);  ${}^{13}C{}^{1}H{}$  NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$ 175.9 (C<sub>carbene-benz</sub>), 170.0 (C<sub>carbene-imi</sub>), 135.8, 134.4, 134.3, 129.6, 129.5, 129.1, 123.5, 122.6, 122.4 (Ar-C, two are coincident), 119.2 (CN) 113.4, 113.3 (Ar-C), 56.1, 54.7, 54.4, 51.0, 37.9, 30.3, 21.1, 21.04, 21.01, 20.8 (CH, CH<sub>2</sub> and CH<sub>3</sub>). Anal. Calcd. for C<sub>27</sub>H<sub>32</sub>I<sub>3</sub>N<sub>5</sub>Pd: C 35.49, H 3.53, N 7.66; found: C 35.88, H 3.68, N 7.92. MS-EI (*m*/*z*): [M – I]<sup>+</sup> calcd for C<sub>27</sub>H<sub>32</sub>I<sub>2</sub>N<sub>5</sub>Pd 786, found 786.



The dimeric complex **2** (94 mg, 0.10 mmol) and benzylimidazole (32 mg, 0.20 mmol) were mixed in DCM (10 mL) and stirred for 2 h before the solvent was evaporated off to afford the product as a yellow solid (123 mg, 0.20 mmol, 98%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$ 

8.35 (s, 1H, NCHN), 7.71 (s, 1H, Imi-H), 7.56–7.59 (m, 2H, Ar-H), 7.35–7.38 (m, 3H, Ar-H), 7.18–7.21 (m, 4H, Ar-H), 6.80 (s, 1H, Imi-H), 6.34 (m,  ${}^{3}J$  = 7 Hz, 2H, NCH), 5.07 (s, 2 H, NCH<sub>2</sub>), 1.75 (d,  ${}^{3}J$  = 7 Hz, 12H, CH<sub>3</sub>);  ${}^{13}C{}^{1}H$  NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  161.5 (C<sub>carbene</sub>), 140.6, 135.4, 134.2, 131.1, 129.8, 129.4, 128.4, 122.8, 119.6, 113.2

(Ar-C), 55.0, 52.4, 21.2 (CH, CH<sub>2</sub> and CH<sub>3</sub>). Anal. Calcd. for C<sub>23</sub>H<sub>28</sub>Br<sub>2</sub>N<sub>4</sub>Pd: C 44.08, H 4.50, N 8.94; found: C 44.35, H 4.67, N 8.63. MS-EI (*m*/*z*): [M −L− Br]<sup>+</sup> calcd for C<sub>13</sub>H<sub>18</sub>BrN<sub>2</sub>Pd 387, found 387.

### NMR Spectra

 $^1H$  and  $^{13}C\{^1H\}$  NMR spectra of 1a.



 $^1H$  and  $^{13}C\{^1H\}$  NMR spectra of 1b.



 $^1H$  and  $^{13}C\{^1H\}$  NMR spectra of 1c.



 $^{1}$ H and  $^{13}$ C{ $^{1}$ H} NMR spectra of 1d.



## <sup>1</sup>H and <sup>13</sup>C{<sup>1</sup>H} NMR spectra of **3a**.



 $^{1}$ H and  $^{13}$ C{ $^{1}$ H} NMR spectra of **3b**.



## $^1H$ and $^{13}C\{^1H\}$ NMR spectra of 3c.



# $^{1}$ H and $^{13}$ C{ $^{1}$ H} NMR spectra of **3d**.



 $^{1}$ H and  $^{13}$ C{ $^{1}$ H} NMR spectra of 4a.



 $^{1}H$  and  $^{13}C\{^{1}H\}$  NMR spectra of 4b.



 $^{1}$ H and  $^{13}$ C{ $^{1}$ H} NMR spectra of **4c**.



 $^{1}$ H and  $^{13}$ C{ $^{1}$ H} NMR spectra of 4d.



## $^{1}$ H and $^{13}$ C{ $^{1}$ H} NMR spectra of **5**.



## $^{1}$ H and $^{13}$ C{ $^{1}$ H} NMR spectra of 6.



 $^1H$  and  $^{13}C\{^1H\}$  NMR spectra of 7a.



<sup>1</sup>H and <sup>13</sup>C{<sup>1</sup>H} NMR spectra of 7d.



## $^{1}$ H and $^{13}$ C{ $^{1}$ H} NMR spectra of 8.



## $^{1}$ H and $^{13}$ C{ $^{1}$ H} NMR spectra of 9.



 $^{1}$ H and  $^{13}$ C{ $^{1}$ H} NMR spectra of **10**.



**X-ray Diffraction Studies**. X-ray data were collected with a Bruker D8 VENTURE diffractometer, using Mo-K $\alpha$  radiation with the SMART suite of Programs.1 The structures were deposited to CCDC database and assigned with numbers of 2226577–2226579. Data were processed and corrected for Lorentz and polarization effects with SAINT, 2 and for absorption effect with SADABS.3 Structural solution and S23 refinement were carried out with the SHELXTL suite of programs.4 The structure was solved by direct methods to locate the heavy atoms, followed by difference maps for the light, non-hydrogen atoms. All non-hydrogen atoms were generally given anisotropic displacement parameters in the final model. All H-atoms were put at calculated positions. A summary of the most important crystallographic data is given in Table S2.

|                          | 3c·THF                                | 4b   | 5                              |
|--------------------------|---------------------------------------|--|--------------------------------|
| formula                  | $C_{32}H_{36}Br_2N_4OPd\cdot C_4H_8O$ | C <sub>27</sub> H <sub>33</sub> BrN <sub>4</sub> O <sub>2</sub> Pd | $C_{23}H_{27}Br_3N_4Pd$        |
| formula weight           | 830.97                                | 631.885  | 705.61                         |
| color, habit             | colorless                             | colorless  | colorless                      |
| temperature [K]          | 150.0                                 | 160.0  | 170.0                          |
| crystal size             | $0.12 \times 0.08 \times 0.05$        | $0.15 \times 0.08 \times 0.06$                                     | $0.12 \times 0.08 \times 0.05$ |
| [mm]                     |                                       |  |                                |
| crystal system           | triclinic                             | monoclinic   | monoclinic                     |
| space group              | P-1                                   | $P2_1/c$   | $P2_1/c$                       |
| <i>a</i> [Å]             | 9.5373(5)                             | 16.1679(6)   | 10.6138(6)                     |
| <i>b</i> [Å]             | 12.3311(7)                            | 9.3786(3)  | 13.7132(9)                     |
| <i>c</i> [Å]             | 16.2241(9)                            | 35.7626(15)  | 17.3306(11)                    |
| α [°]                    | 93.233(2)                             | 90   | 90                             |
| β[°]                     | 92.079(2)                             | 96.1070(10)  | 97.572(2)                      |
| γ [°]                    | 110.721(2)                            | 90   | 90                             |
| V [Å <sup>3</sup> ]      | 1778.54(17)                           | 5392.0(3)  | 2500.5(3)                      |
| Ζ                        | 2                                     | 8  | 4                              |
| Dc (g cm <sup>-3</sup> ) | 1.552                                 | 1.557  | 1.874                          |
| radiation used           | Μο Κα                                 | Μο Κα  | Μο Κα                          |
|                          |                                       |  |                                |

Table S2. Selected X-ray crystallographic data for complexes 3c, 4b and 5

| $\mu \text{ [mm-1]}$        | 2.805           | 2.201           | 5.554                   |
|-----------------------------|-----------------|-----------------|-------------------------|
| $\theta$ range (°)          | 4.192–50.736    | 4.492-52.804    | 3.872-52.786            |
| no. of unique               | 6404            | 47847           | 5091                    |
| data                        |                 |                 |                         |
| final R indices             | $R_1 = 0.0414$  | $R_1 = 0.0489$  | $R_1 = 0.0821$          |
| $[I > 2\sigma(I)]$          | $wR_2 = 0.0855$ | $wR_2 = 0.0978$ | wR <sub>2</sub> =0.1548 |
| R indices (all              | $R_1 = 0.0614$  | $R_1 = 0.0886$  | $R_1 = 0.1408$          |
| data)                       | $wR_2 = 0.0958$ | $wR_2 = 0.1157$ | $wR_2 = 0.1747$         |
| goodness-of-fit             | 0.990           | 1.028           | 1.066                   |
| on $F^2$                    |                 |                 |                         |
| peak/hole [e Å <sup>-</sup> | 0.88/-0.56      | 1.29/-1.02      | 1.90/-1.35              |
| 3]                          |                 |                 |                         |



Figure S2 Molecular structure of racemic **4b** showing 50% probability ellipsoids; most hydrogen atoms are omitted for clarity.

#### Reference

1 H. V. Huynh, Y. Han, R. Jothibasu and J. A. Yang, <sup>13</sup>C NMR Spectroscopic Determination of Ligand Donor Strengths Using N-Heterocyclic Carbene Complexes of Palladium(II), *Organometallics*, 2009, **28**, 5395-5404.

2 C. Hansch. A. Leo and R. W. Taft, A Survey of Hammett Substituent Constants and Resonance and Field Parameters, *Chem. Rev.*, 1991, **91**, 165-195.

3 A. D. Becke, Density-functional thermochemistry. III. The role of exact exchange. *J. Chem. Phys.*, **1993**, *98*, 5648–5652.

4 A. Kumar, D. Yuan and H. V. Huynh, Stereoelectronic Profiling of Expanded-Ring N-Heterocyclic Carbenes, *Inorg. Chem.*, 2019, **58**, 7545-7553.

5 Kodolitsch. K, Gobec. F, Slugovc. C. Solvent- and Catalyst-Free Aza-Michael Addition of Imidazoles and Related Heterocycles. *Eur. J. Org. Chem.*, 2020, **19**, 2973-2978.

6 Kumar. L, Sarswat A, Lal. N. Design and synthesis of 3-(azol-1-yl) phenylpropanes as microbicidal spermicides for prophylactic contraception. *Bioorg. Med. Chem. Lett.*, 2011, **21**,176-181.

7 M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G. A. Petersson, H. Nakatsuji, M. Caricato, X. Li, H. P. Hratchian, A. F. Izmaylov, J. Bloino, G. Zheng, J. L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J. A. Montgomery, Jr., J. E. Peralta, F. Ogliaro, M. Bearpark, J. J. Heyd, E. Brothers, K. N. Kudin, V. N. Staroverov, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, N. Rega, N. J. Millam, M. Klene, J. E. Knox, J. B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski, R. L. Martin, K. Morokuma, V. G. Zakrzewski, G. A. Voth, P. Salvador, J. J. Dannenberg, S. Dapprich, A. D. Daniels, Ö. Farkas, J. B. Foresman, J. V. Ortiz, J. Cioslowski, D. J. Fox, *Gaussian 09, Revision A.2*, Gaussian, Inc., Wallingford, CT, 2009.